Table 1.
Patients’ characteristics
| Age (years) | 65.9 (50–85) |
|---|---|
| initial PSA (ng/mL) | 15.6 (2.6–173) |
| Primary diagnosis validated by histopathology | 100/100 (100%) |
| ISUP grade at diagnosis | |
| ISUP grade 1 | 15 (15%) |
| ISUP grade 2 | 25 (25%) |
| ISUP grade 3 | 27 (27%) |
| ISUP grade 4 | 16 (16%) |
| ISUP grade 5 | 17 (17%) |
| Initial treatment | |
| Surgery | 82 (77) |
| Radiotherapy ± ADT | 17 (17%) |
| Adiuvant radiotherapy | 16 (16%) |
| Adiuvant ADT | 30 (30%) |
| PSA nadir (ng/mL) | 0.16 (0.00–4.15) |
| Salvage radiotherapy | 23/82 (28%) |
| Setting of PET/CT restaging | |
| First time BCR | 42 (42%) |
| BCR after salvage radiotherapy | 35 (35%) |
| Biochemical persistence after surgery | 9 (9%) |
| Biochemical progression during ADT | 14 (14%) |
| PSA and PSA kinetics at BCR | |
| PSA (ng/mL) | 1.6 (0.18–27.2) |
| PSAdt (months) | 9.7 (0.2–53) |
| PSAvel (ng/mL/year) | 1.9 (0.1–53.1) |
| ADT at PET/CT | 18 (18%) |
| Interval between initial treatment and BCR (months) | 45.2 (1–190) |
| PET/CT pretest probability* | 48.8% (4–96%) |
PSA prostate-specific antigen, ISUP International Society of Urological Pathology, ADT androgen deprivation therapy, PET/CT positron emission tomography/computed tomography, BCR biochemical recurrence, PSAdt prostate-specific antigen doubling time, PSAvel prostate-specific antigen velocity; * defined according to [12, 13]